Atila Cihan, Monnerat Sophie, Bingisser Roland, Siegemund Martin, Lampart Maurin, Rueegg Marco, Zellweger Núria, Osswald Stefan, Rentsch Katharina, Christ-Crain Mirjam, Twerenbold Raphael
Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.
Department of Clinical Research, University of Basel, Basel, Switzerland.
Endocr Connect. 2022 Sep 26;11(10). doi: 10.1530/EC-22-0171. Print 2022 Oct 1.
Hyponatremia in COVID-19 is often due to the syndrome of inadequate antidiuresis (SIAD), possibly mediated by interleukin-6 (IL-6)-induced non-osmotic arginine vasopressin (AVP) secretion. We hypothesized an inverse association between IL-6 and plasma sodium concentration, stronger in COVID-19 compared to other respiratory infections.
Secondary analysis of a prospective cohort study including patients with COVID-19 suspicion admitted to the Emergency Department, University Hospital of Basel, Switzerland, between March and July 2020.
We included patients with PCR-confirmed COVID-19 and patients with similar symptoms, further subclassified into bacterial and other viral respiratory infections. The primary objective was to investigate the association between plasma sodium and IL-6 levels.
A total of 500 patients were included, 184 (37%) with COVID-19, 92 (18%) with bacterial respiratory infections, and 224 (45%) with other viral respiratory infections. In all groups, median (IQR) IL-6 levels were significantly higher in hyponatremic compared to normonatremic patients (COVID-19: 43.4 (28.4, 59.8) vs 9.2 (2.8, 32.7) pg/mL, P < 0.001; bacterial: 122.1 (63.0, 282.0) vs 67.1 (24.9, 252.0) pg/mL, P < 0.05; viral: 14.1 (6.9, 84.7) vs 4.3 (2.1, 14.4) pg/mL, P < 0.05). IL-6 levels were negatively correlated with plasma sodium levels in COVID-19, whereas the correlation in bacterial and other viral infections was weaker (COVID-19: R = -0.48, P < 0.001; bacterial: R = -0.25, P = 0.05, viral: R = -0.27, P < 0.001).
IL-6 levels were inversely correlated with plasma sodium levels, with a stronger correlation in COVID-19 compared to bacterial and other viral infections. IL-6 might stimulate AVP secretion and lead to higher rates of hyponatremia due to the SIAD in these patients.
新型冠状病毒肺炎(COVID-19)中的低钠血症通常归因于抗利尿激素分泌不足综合征(SIAD),可能由白细胞介素-6(IL-6)诱导的非渗透性精氨酸加压素(AVP)分泌介导。我们推测IL-6与血浆钠浓度呈负相关,在COVID-19中这种相关性比其他呼吸道感染更强。
对一项前瞻性队列研究进行二次分析,该研究纳入了2020年3月至7月间入住瑞士巴塞尔大学医院急诊科且疑似患有COVID-19的患者。
我们纳入了PCR确诊的COVID-19患者以及有类似症状的患者,后者进一步细分为细菌性和其他病毒性呼吸道感染患者。主要目的是研究血浆钠与IL-6水平之间的关联。
共纳入500例患者,其中184例(37%)为COVID-19患者,92例(18%)为细菌性呼吸道感染患者,224例(45%)为其他病毒性呼吸道感染患者。在所有组中,低钠血症患者的IL-6水平中位数(IQR)显著高于血钠正常的患者(COVID-19组:43.4(28.4,59.8) vs 9.2(2.8,32.7)pg/mL,P < 0.001;细菌感染组:122.1(63.0,282.0) vs 67.1(24.9,252.0)pg/mL,P < 0.05;病毒感染组:14.1(6.9,84.7) vs 4.3(2.1,14.4)pg/mL,P < 0.05)。在COVID-19中,IL-6水平与血浆钠水平呈负相关,而在细菌性和其他病毒感染中的相关性较弱(COVID-19组:R = -0.48,P < 0.001;细菌感染组:R = -0.25,P = 0.05,病毒感染组:R = -0.27,P < 0.001)。
IL-6水平与血浆钠水平呈负相关,在COVID-19中的相关性比细菌性和其他病毒感染更强。IL-6可能刺激AVP分泌,并导致这些患者因SIAD出现更高的低钠血症发生率。